BioSpace News Archive

AZTherapies, Inc. , a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the dosing of the first patient in its Phase 2a clinical trial examining the safety and efficacy of ALZT-OP1a in patients with mild- to moderate-stage Amyotrophic Lateral Sclerosis (ALS). ALZT-OP1a is the company’s proprietary inhaled formulation of cromolyn, engineered to improve blood brain barrier permeability and bioa

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has received approval of its Investigational Medicinal Product Dossier (IMPD) from the French regulatory authority,

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences. The H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15 th at 10am EST The 2020 Cantor Global Healthcare Conference on Wednesday, September 16 th at 4:00pm EST The Oppenheimer Fall Healthcare Summit on Monday, Sep

TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that the Company’s President Mr. George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD, will be presenting at HC Wainwright & Co’s 22nd Annual Global Investment Conference on Monday, September 14, 2020, at 10:00am ET.

Vantage Galan with Advanced intelligent Clear-IQ Engine Provides High-Quality Images and Fast Exam Times

Brian J. Brille to present a fireside chat covering molecular science and precision medicine.

Benchmark Appointed Key Manufacturing Partner To Scale Delivery of DnaNudge’s RT-PCR Test, Now In Major Global Demand to Aid Fight Against COVID-19

Murphy brings a wealth of life sciences capital markets experience and deep knowledge in the enabling technologies and cell therapy sectors

Peptilogics announced that the US Food and Drug Administration has granted Orphan Drug Designation for PLG0206, the company’s first-in-class, broad-spectrum antibiotic peptide, for the treatment of prosthetic joint infections, a rare life-threatening condition that may result from arthroplasty or joint replacement procedures.

New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system